Main Menu

Neon Therapeutics, Inc.

(NASDAQ GS: NTGN)

Summary

Attention investors who purchased shares of Neon Therapeutics, Inc. before January 16, 2020:

Rigrodsky & Long is investigating potential claims against the board of directors of Neon Therapeutics, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by BioNTech SE for approximately $67 million.

Press Release

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors Neon Therapeutics, Inc. (“Neon” or the “Company”) (NASDAQ GS: NTGN) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by BioNTech SE (“BioNTech”) (NASDAQ GS: BNTX) in a transaction valued at approximately $67 million. Under the terms of the agreement, shareholders of Neon will receive 0.063 American Depository Shares, which are equivalent to one ordinary share of BioNTech, for each share of Neon they own.

If you own common stock of Neon and purchased any shares before January 16, 2020, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.  

Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Back to Page